

## Minutes of the HPRA Leadership Team

### Licensing and regulation section

---

- Friday 17 October 2025 at 9.30am
- Hybrid Teams call and CEO's meeting room 3<sup>rd</sup> floor

| Chair                                 | Present                                                   | Apologies                                          |
|---------------------------------------|-----------------------------------------------------------|----------------------------------------------------|
| Ms R. Purcell, Deputy Chief Executive | Ms. N. Riggs, Director of Human Resources and Development | Dr L. Nolan, Chief Executive                       |
|                                       | Dr F. Lonsdale, Director of Human Medicines               | Mr S. d'Art, Director of ICT and Business Services |
|                                       | Dr N. MacAleenan, Director of Medical Devices             | Ms G. Power, Director of Compliance                |
|                                       | Ms S. Curran, Director of Human Products Monitoring       |                                                    |
|                                       | Dr D. Murphy, Director of Veterinary Science              |                                                    |

Minutes taken by Ms A. Holly, Corporate Affairs Manager

Please note that certain information, such as personal data, confidential/commercially sensitive information, and pending prosecutions may have been removed from these minutes.

\*Approved via written procedure

\*\*Attended part of the meeting

#### 1 ADOPTION OF THE AGENDA

The meeting adopted the agenda.

#### 2 DECLARATIONS OF INTEREST

There was nothing to report.

#### 3 ADOPTION OF THE MINUTES OF THE LAST MEETING

The minutes of the meeting of 10 October 2025 were adopted and signed.

#### **4 MATTERS ARISING**

##### Sodium Valproate

An update was provided on the status of national stakeholder engagements regarding the pregnancy prevention programme.

##### Veterinary inspection

HLT received an update on a potential issue identified during a recent inspection of a veterinary manufacturing site. The HPRA is reviewing the inspection findings and will determine any necessary regulatory follow-up once the final report is available.

#### **5 PUBLIC HEALTH ISSUES**

There was nothing to report.

#### **6 PRODUCT ISSUES**

##### Closantel withdrawal period update

HLT was provided an update on Closantel-containing products for sheep. The HPRA has extended the withdrawal period for certain products from 42 to 56 days as a precautionary measure to protect consumer safety. A safety notice has been published advising users to apply the revised withdrawal period immediately.

#### **7 REJECTIONS, SUSPENSIONS AND REVOCATIONS**

There was nothing to report.

#### **8 LICENSING TABLES**

The relevant tables submitted were approved.

#### **9 AOB**

##### Notifiable Incident Reporting

HLT was informed that the HPRA and HIQA recently met to discuss alignment of processes for incident notifications and follow-up under the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023. Further updates will be provided as this work progresses.